Update on the Management of Ocular Surface Squamous Neoplasia.

IF 0.9 Q4 OPHTHALMOLOGY Current Ophthalmology Reports Pub Date : 2021-03-01 Epub Date: 2021-02-20 DOI:10.1007/s40135-020-00260-y

Umangi Patel, Carol L Karp, Sander R Dubovy

{"title":"Update on the Management of Ocular Surface Squamous Neoplasia.","authors":"Umangi Patel, Carol L Karp, Sander R Dubovy","doi":"10.1007/s40135-020-00260-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: To review and update the latest findings in diagnosis and management of ocular surface squamous neoplasia (OSSN).Recent findings: OSSN is the most common anterior segment neoplastic disease process. Several ocular surface imaging techniques have been developed for the early diagnosis and management of clinical and subclinical ocular surface squamous neoplasia, including high-resolution optical coherence tomography (HR-OCT), in vivo confocal microscopy, and ultrasound biomicroscopy. Treatment modalities include both surgical and medical management, with a recent trend towards primary and adjunctive pharmacotherapy.Summary: There is increasing use of HR-OCT for the diagnosis and monitoring of clinical and subclinical OSSN lesions. Topical pharmacotherapy agents, including interferon α-2b, 5-fluorouracil, and mitomycin C, have demonstrable efficacy in the treatment of OSSN and their use may be dictated based upon tumor factors, patient factors, cost, and side effect profile. Both surgical excision and adjunctive topical medications have excellent success, with the favored treatment method trending towards topical pharmacotherapy as primary therapy.","PeriodicalId":10836,"journal":{"name":"Current Ophthalmology Reports","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40135-020-00260-y","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Ophthalmology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40135-020-00260-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/2/20 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 7

Abstract

Purpose of review: To review and update the latest findings in diagnosis and management of ocular surface squamous neoplasia (OSSN).

Recent findings: OSSN is the most common anterior segment neoplastic disease process. Several ocular surface imaging techniques have been developed for the early diagnosis and management of clinical and subclinical ocular surface squamous neoplasia, including high-resolution optical coherence tomography (HR-OCT), in vivo confocal microscopy, and ultrasound biomicroscopy. Treatment modalities include both surgical and medical management, with a recent trend towards primary and adjunctive pharmacotherapy.

Summary: There is increasing use of HR-OCT for the diagnosis and monitoring of clinical and subclinical OSSN lesions. Topical pharmacotherapy agents, including interferon α-2b, 5-fluorouracil, and mitomycin C, have demonstrable efficacy in the treatment of OSSN and their use may be dictated based upon tumor factors, patient factors, cost, and side effect profile. Both surgical excision and adjunctive topical medications have excellent success, with the favored treatment method trending towards topical pharmacotherapy as primary therapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

眼表鳞状瘤状病变的治疗进展。

综述目的:回顾和更新眼表鳞状瘤状病变(OSSN)的诊断和治疗的最新发现。最近的研究发现:OSSN是最常见的前段肿瘤病变过程。几种眼表面成像技术已被开发用于临床和亚临床眼表面鳞状瘤样病变的早期诊断和治疗，包括高分辨率光学相干断层扫描(HR-OCT)、体内共聚焦显微镜和超声生物显微镜。治疗方式包括手术和医疗管理，最近的趋势是主要和辅助药物治疗。摘要:越来越多的人使用HR-OCT来诊断和监测临床和亚临床OSSN病变。局部药物治疗药物，包括干扰素α-2b、5-氟尿嘧啶和丝裂霉素C，在治疗OSSN方面有明显的疗效，它们的使用可能取决于肿瘤因素、患者因素、成本和副作用。手术切除和辅助局部药物治疗均取得了良好的效果，治疗方法倾向于局部药物治疗作为主要治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Ophthalmology Reports Medicine-Ophthalmology

CiteScore

2.00

自引率

0.00%

发文量

期刊介绍： This journal aims to offer expert review articles on the most significant recent developments in the field of ophthalmology. By providing clear, insightful, balanced contributions, the journal intends to serve those who diagnose, treat, manage, and prevent ocular conditions and diseases. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas across the field. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An Editorial Board of more than 20 internationally diverse members reviews the annual table of contents, ensures that topics include emerging research, and suggests topics of special importance to their country/region. Topics covered may include age-related macular degeneration; diabetic retinopathy; dry eye syndrome; glaucoma; pediatric ophthalmology; ocular infections; refractive surgery; and stem cell therapy.